Creative Biolabs' Bispecific Antibody Conjugate Solutions Push Forward A Positive Synergy

New York City, New York Mar 5, 2023 (Issuewire.com) - After the era of chemotherapy, targeted therapy, and immunotherapy, antibody-drug conjugate (ADC) drugs have opened the era of fourth-generation drug therapy for oncology with remarkable achievements. More than 100 years have passed since the concept of ADC was introduced, and technological advances have led to the emergence of various novel conjugate drugs. To push forward a positive synergy of bispecific antibody (bsAb)-based conjugate drugs, Creative Biolabs has integrated the comprehensive portfolio of bsAb services with cutting-edge conjugation technology to facilitate the research on bsAb-drug conjugates and bsAb-cell conjugates.

* Bispecific Antibody-Drug Conjugate Development Service

The progress in antibody engineering and in ADC technology make it an ideal opportunity to develop bispecific ADCs. Powered by rich experience in bsAb design and development,  Creative Biolabs can precisely design or modify promising bispecific ADCs with quality controls on the optimization of cytotoxic delivery, enhanced ADC uptake, and effective lysosomal trafficking.

For the selection of bispecific formats for ADC, Creative Biolabs offers a wide range of bsAb formats for ADC drug development and is able to assist clients in selecting the suitable binding modality to match the proposed mechanisms of action and the specific clinical applications. To enhance selectivity, Creative Biolabs is proficient in utilizing bispecific technology to increase the ability of ADC targeting and selectivity, among which, dual targeting is the strategy that is most used to extend the reach of an ADC. The scientific team has also developed novel bispecific-based strategies, and two main methods, fast-internalizing receptors and crosslinking and clustering of receptors are applied to promote endocytosis and lysosomal trafficking.

* Bispecific Antibody-Cell Conjugate Development Service

CellFace conjugate technology at Creative Biolabs is one of the most advanced cell surface engineering technology platforms, which allows for a stable conjugation of any biomolecule on the cell surface, while maintaining the cell viability, especially for cell-antibody conjugate. With this platform, the specialists can support the whole workflow for bsAb-cell conjugate discovery and development.

For the design part, Creative Biolabs offers hundreds of validated cell lines, covering cancer cell lines, immune cell lines, stem cells, and control cell lines. For the conjugation, fucosyltransferases (Fuc T) are well implemented to transfer antibodies to the surface of living cells in minutes without genetic modification of the host cells. The team also provides a full set of cell-antibody conjugate characterization services to analyze antibody labeling efficiency and anti-tumor efficacy in vitro and in vivo, including antibody labeling efficiency analysis, antibody-dependent cellular cytotoxicity (ADCC) analysis, and antibody-antigen binding analysis.

Creative Biolabs highlights the flexibility and can adapt every process to clients' specific projects. More information can be found at https://www.creative-biolabs.com/bsab/.

About Creative Biolabs

With more than a decade of exploration and expansion, Creative Biolabs has been dedicated to offering services on antibody discovery, engineering, production, and analysis. Especially, the bispecific antibody (BsAb) team has gathered a collective of experienced scientists committed to providing high-quality services to customers all over the world, covering BsAb design, purification, engineering, manufacturing, and BsAb analysis service.

Media Contact

Creative Biolabs

[email protected]

https://www.creative-biolabs.com/bsab/